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Immunotherapy in vivo with antibodies directed against T lymphocytes has
been successfully used for immunosuppression in patients after organ transplan-
tation, as well as in murine autoimmune disease models (1-4) . The suppressive
effect of such immunotherapy has been directly correlated with reductions in
target cell numbers (5) . Generation of mAbs with specificity for defined T cell
subsets may allow a limited selectivity in this type of manipulation of the immune
response . Although some monoclonal reagents have been extremely effective in
eliminating T cells in vivo, the immunosuppressive effect generated has been
transient and has lacked antigen specificity (6, 7) .
Experiments in vitro and adoptive transfer of lymphocytes into irradiated
recipients have shown that the generation of a humoral immune response against
most antigens is T cell-dependent . Regulation and amplification of B cell
function has been attributed to aT cell subset, which by cell surface phenotyping
is characterized by the expression of a nonpolymorphic cell surface marker, the
L3T4 molecule (8) . This molecule is intimately involved in T cell activation ;
mAbs against L3T4 can specifically blockTh cell effector functions in vitro. The
presence of the L3T4 molecule is generally correlated with the specificity of
matureT cells for MHC class II restriction elements (9, 10). Although there is a
striking correlation between L3T4 expression and restriction specificity forMHC
class 11 molecules, recent data (11) suggest that L3T4 maynotrepresent a ligand-
binding molecule for MHC class II molecules . The mechanism of action of the
L3T4 molecule is unresolved .
It was the aim of this study to explore the function of L3T4+ T lymphocytes
in the initiation and differentiation of a humoral immune response in vivo . An
additional objective was to analyze the immunocompetence of adult mice that
had undergone helper cell depletion . A helper cell-deficient state may be
associated with the induction of neonatal tolerance (12) . During the early
differentiation of the immune system the primary development of the T and B
cell repertoire has been shown to be under genetic control (13, 14). Other
mechanisms including antigen-driven differentiation might shape an individual's
clonal profile (15, 16) . The presence of soluble antigen in the periphery may
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influence the relative frequencies of T cell and B cell clonotypes, which are
subsequently expressed by the mature immune system. Elimination of L3T4+
Th cells in adult mice might make it possible to mimic neonatal conditions, and
repeated injections ofantigen during the early phase of the helper cell depletion
and regeneration might help us study the influence of antigen on the ultimate
composition of the T and B cell repertoire.
We established a model system in which the L3T4+ T cell subpopulation could
be depletedin vivo by injection ofanti-L3T4 mAbintoadult mice. We monitored
short-term, as well as long-term effects ofthe antibody treatment on the humoral
immune responses against sperm whale myoglobin (SpWMb)' and KLH. After
treatment with anti-L3T4 in vivo, adult mice did not develop primary humoral
immune responsiveness against SpWMb or KLH. Such helper cell-depleted mice
regained their ability to produce anti-KLH antibodies coincident with the recov-
ery of the L3T4+ T cell subset, whereas we saw long lasting unresponsiveness
against SpWMb which exceeded the apparent regeneration of the helper cell
population. This long-term unresponsiveness to SpWMb could not be achieved
in animals after memory induction. Thus, the immunosuppressive effect of anti-
L3T4 therapy seemed to be determined in part by the preexisting T cell
repertoire. The observed long-term unresponsiveness against SpWMb might
suggest thatthe recovery ofthe L3T4 T cellpopulationafter helper cell depletion
was a nonrandom process influenced by the presence of soluble antigen in the
periphery.
Materials and Methods
Mice.
￿
BALB/c mice (6-8 wk old) were purchased from TheJackson Laboratory, Bar
Harbor, ME.
Antigens.
￿
SpWMb was obtained from Sigma Chemical Co. (St. Louis, MO), and KLH
was purchased from Calbiochem-Behring Corp., San Diego, CA.
Monoclonal Antibodies.
￿
The rat anti-mouse hybridoma GK1 .5 was kindly provided by
Dr. F . Fitch, University of Chicago. The antibody reacts with the L3T4 (CD4) molecules,
and has been shown (8) to be of the IgG2b subclass. We obtained large amounts of
purified antibody by passage ofascites over an affi-gel blue column (Bio-Rad Laboratories,
Richmond, CA). The rat mAbs anti-Lyt-1 (hybridoma 53-7.2) and anti-Lyt-2 (hybridoma
53-6.7) have been described by Ledbetter et al. (17). Purified mouse mAb against rat K
chains (clone MAR 18 .5, mouse IgG2a) was kindly provided by the laboratory of Dr. L.
Herzenberg, Stanford University.
Fluorochrome Coupling. Biotin and fluorescein were purchased from Bio-Research,
San Rafael, CA. Conjugated Texas Red avidin was obtained from Becton Dickinson &
Co., Mountain View, CA. Biotinylation and fluorochrome conjugation have been de-
scribed in detail (18, 19). Briefly, conjugations were performed in a carbonate/bicarbonate
buffer at pH 9.3 for 4 h (biotin) or 2 h (fluorescein) at room temperature. Reagents were
stored at 4°C with 0.1% azide. Immediately before use, they were deaggregated by
spinning in a Beckman Airfuge (Beckman Instruments, Inc., Fullerton, CA) at 100,000 g
for 10 minutes.
Staining Procedure.
￿
Lymph node cell suspensions of normal and treated mice were
prepared in PBS containing 2% FCS and 0 .1% sodium azide, and they were depleted of
erythrocytes by gradient centrifugation on Ficoll-Hypaque. 5 X 105 cells were incubated
in 25 pl of pretitered, conjugated antibody for 30 min on ice and were washed twice. For
two-color analysis, green fluorescence was derived from directly FITC-conjugated re-
agents (anti-L3T4, anti-Lyt-2). In a second incubation, Texas Red-labeled avidin was
added and bound to biotinylated first-step antibody (anti-Lyt-1). As controls for back-
'Abbreviation used in this paper:
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ground fluorescence levels, we analyzed control cell preparations that were either un-
stained or incubated with an isotype-matched irrelevant antibody. Flow microfluorometry
analysis was performed on a modified FACS II system (Becton Dickinson Immunocy-
tometry Systems, Mountain View, CA) equipped with logarithmic amplifiers. Data analysis
by the VAX computer system has been previously described (20). Dead cellswere excluded
from analysis by the scatter gating method, and additionally by propidium iodine staining
at a final concentration of 1 ug/ml. Data are presented on logo scales of increasing green
and red fluorescence intensity, and are shown as contour plots.
Immunization.
￿
Mice were immunized with 100,ug SpWMb or KLH intraperitoneally
or received 100 Ag of antigen emulsified in CFA. On day -1, 0, and 1, mice were injected
intraperitoneally with purified anti-L3T4 mAb. Unless the experimental design required
titrations of the antibody dose, the mice received 200 ug at each single dose. Sera were
collected on days 6, 8, and 14 after immunization. 2 wk after the first antigen injection,
the animals were boosted intraperitoneally with 100 ug aqueous antigen, and were
challenged with a constant dose of 100 mg antigen at 2 wk intervals.
IL-2 Treatment. rIL-2 was used for reconstitution experiments. The recombinant
product (No. 9C), as well as a buffer control, was kindly supplied by Cetus Corp.,
Emeryville, CA. In treatment experiments, each mouse received 200 ug anti-L3T4 on
day -1, 0, and 1, followed by three daily injections of 5,000 U rIL-2 at day 1, 2, and 3 .
Control animals were injected with the control buffer to exclude nonspecific effects such
as endotoxin contaminants.
LPS Stimulation In Vitro.
￿
Spleen cells of normal and treated animals were suspended
in RPMI 1640 medium supplemented with 5% pretested FCS, 2 mM glutamine, and 10
mM HEPES. B cells were polyclonally stimulated in microcultures containing 2 X 105
spleen cells and 1 % LPS in a total volume of 200 jul. Supernatants were harvested on day
3 and day 4, and secreted antibodies were measured in an ELISA system.
Determination of Antibody Titers.
￿
Antibody concentrations in sera and culture super-
natants were determined in a solid-phase ELISA system (21). KLH or SpWMb was coated
onto microtiter plates (Dynatech Laboratories, Inc., Alexandria, VA) by overnight incu-
bation with PBS containing 100 wg/ml antigen. The remaining binding siteswere saturated
with a 2% BSA solution during a 3-h incubation at 37°C. Plates were washed extensively
with PBS (0.05% Tween 20) and incubated with 50-itl aliquots of diluted serum for 2 h
at room temperature. Antibodies fixed to the solid antigen phase were detected by using
a pretitered goat anti-mouse Ig coupled with peroxidase. The developing reagents for
total Igs were purchased from Tago Inc., Burlingame, CA. Goat anti-mouse antibodies
specific for the isotypes IgG and IgM were obtained from Cappel Laboratories, Cochran-
ville, PA. After incubation with the second stage antisera, plates were washed and
developed using O-phenylenediamine dihydrochloride (1 mg/ml) and H202 as substrates
in 0.1 M citric acid pH 4.5. 4 M H2SOq was added to stop the reaction, and the OD480
was measured by an ELISA reader (Titertek Multiscan, Flow Laboratories, Inc., McLean,
VA). Assays were standardized by using affinity purified hyperimmune sera against
SpWMb or KLH.
Results
Elimination of L3T4' T Cells by Treatment In Vivo with anti-L3T4
mAb. Treatment in vivo with mAbs against the L3T4 molecule (CD4) has been
used successfully to block certain T cell functions in mice (5). The mechanism(s)
of action of the injected antibody is not clear. We used two-color FACS analysis
to examine the effect of anti-L3T4 treatment in vivo on lymph node T cells.
Directly conjugated reagents were used to detect the Lyt-1, the Lyt-2, and the
L3T4 cell surface markers. Increasing amounts of purified anti-L3T4 mAb
injected intraperitoneally caused a dose-dependent depletion of L3T4' T cells
from the lymph nodes (Fig. 1). Amounts as little as 10 jug mAb given on each of
3 d were sufficient to eliminate 65% of the L3T4-expressing T cell subset (Table
1). Injection of 50 Ag mAb anti-L3T4 per day for 3 d depleted >90% of L3T4'914
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FIGURE 1 . Two-color immunofluorescence analysis of lymph node cells after anti-L3T4
treatment in vivo . Doses of 10, 50, 100, and 200 ug anti-L3T4 mAb were injected into
BALB/c mice on each of 3 consecutive days. Lymph nodes were harvested the day after
termination of antibody treatment . Cells were stained with biotin coupled anti-Lyt-1 (hybri-
doma 53-72), and with fluorescence-labeled anti-L3T4 (hybridoma GK1 .5) or anti-Lyt-2
(hybridoma 53-67) . The biotinylated antibody bound to the cell surface was detected by Texas
Red-labeled avidin as a second step reagent . Relative densities of the stained cell surface
markers are represented as fluorescence intensity on logo scales. Contour plots are used to
express levels of green andred fluorescence . LN, lymph node cells .
T cells in the lymph nodes . A complete elimination of the L3T4' T cell subset
was not achieved with antibody doses as high as 200 wg given on each of 3
consecutive days . After a total of 600 ug anti-L3T4, 5% of the remaining Lyt-
1+ T cells exhibited dull staining for the L3T4 cell surface marker by FAGS
analysis . Elimination of L3T4+ T cells from the lymph nodes of treated animals
was accompanied by a compensatory increase in cells of the Lyt-1 +,Lyt-2- '-
phenotype (Table I) . In addition, we found a small population of Lyt-l+,Lyt-2-TABLE I
Dose-dependent Elimination ofL3T4+ Lymph Node Cells After Treatment with Anti-L3T4 In
Vivo
BALB/c mice were treated with the indicated doses of anti-L3T4 antibody; lymph node cells were
harvested and analyzed for the expression of cell surface markers as described in the legend to Fig.
1 . Number of Lyt-I+,Lyt-2-,L3T4- wascalculated by the formula: Lyt-1+,Lyt-2-,L3T4- = Lyt-1+ -
(Lyt-1 +,Lyt-2+ + Lyt-1+,L3T4+).
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Reappearance of L3T4+ T lymphocytes in lymph nodes of anti-L3T4-treated
mice. BALB/c mice were injected intraperitoneally with 200,ug of anti-L3T4 mAb on each
of 3 consecutive days. Cervical, axillary, and inguinal lymph node cells of three mice were
pooled andcell surface phenotypes were analyzed by two-color FACS analysis before, and 2,
14, 28, and 37 days after treatment. Total numbers of harvested lymph node cells were 1.79
x 107, 1 .3 x 107, 1 .52 x 107, 1 .7 x 107, and 1 .72 x 107, respectively, for the different days.
Lyt-1 was used as a global T cell marker. Lymph node cells staining for L3T4 or Lyt-2 are
expressed as percentages of total T lymphocytes.
lymph node cells in treated mice which exceeded the number of the remaining
L3T4+ cells. We analyzed these double negative cells (Lyt2-,L3T4-) for direct
binding of a mouse mAb against rat is chains to examine the possibility that
residual rat anti-L3T4 antibody remained bound to certain L3T4+ cells. A
subpopulation of about 6-9% of lymph node cells reacted with the anti rat K
chain antibody, suggesting that some L3T' cells remained that had bound rat
anti-mouse L3T4 antibodies. However, this subpopulation could not totally
account for the double negative cells, suggesting the emergence of a small
percentage of cells that had lost the expression of the L3T4 marker. Thus,
treatment in vivo with anti-L3T4 resulted in a depletion of most, but not all,
L3T4'' T cells from lymph nodes.
We analyzed lymph node cells of BALB/c mice for several weeks after the
termination ofantibody treatment to study the persistence of the effects in vivo.
As shown in Fig. 2, mice treated with a total dose of 300 ug anti-L3T4 in three
divided doses had a long-term inversion of the L3T4/Lyt-2 ratio. For at least 4
Antibody treat- Total Percent lymph node cells expressing:
ment with anti-
L3T3(d j;for
lymph
(X10ells
Lyt-1+ L3T4+ Lyt-2+ Lyt2-
Rat Ig
Lyt-1+
Lyt-2-, ,
L3T4-
Ratio of
L3T4/Lyt-2
None 1 .81 64.1 46.9 18.1 46.0 0 0 2.6
10 1 .53 52.0 13.1 32.4 19.6 6.0 6.5 0.4
50 1 .46 50.9 4.6 34.3 16.6 8.8 12.0 0.13
100 1 .29 56.2 2 .0 42.3 13.5 9.3 11 .9 0.05
200 1 .28 53.9 2.7 38.3 15.6 8.6 12.9 0 .07916
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FIGURE 3. Primary immune responses against soluble antigens in mice treated with anti-
L3T4 . (A) BALB/c mice were immunized with 100 Ag aqueous SpWMb on day 0. Mice
received either 200 ug ofanti-L3T4 thedaybefore, thedayof, andtheday after immunization
(A), or were untreated (El). Sera before immunization (9) and collected 8 d after antigen
injections were analyzed for SpWMb-specific antibodies. Results representmeans offour mice
in each group. (B) BALB/c mice were depleted of helper cells by injection of 200 Ag anti-
L3T4 over 3 d. On the second day they were immunized with 100 wg KLH. Titers of KLH-
specific IgM and IgG in control animals(p) and antibody treated mice (A) were measured at
day 8 after immunization. Each group consisted of four mice. Results aregiven as means.
wk, the majority of lymph node cells expressed the Lyt-2 marker. During the
early posttreatment period a slow increase in L3T4+ cells was correlated with
the disappearance of double negative Lyt-1+ lymph node cells. The repopulation
of lymph nodes with L3T4'* T cells was dose-dependent. Mice treated with three
doses of 10 jAg anti-L3T4 regained 50% of the L3T4 subpopulations within 2
wk after the treatment (data not shown). Injection of higher doses caused an
imbalance of peripheral T cell subsets for >4 wk.
Effect of Anti-1,3T4 Treatment on the Primary Humoral Immune Response.
Treatment in vivo with anti-L3T4 provided a reproducible animal model to
study the effects of altered T cell composition on immune response . We analyzed
the effect of anti-L3T4 injections on the humoral immune response against two
soluble antigens, SpWMb and KLH. Immunization of normal untreated BALB/c
mice with 100 ug soluble SpWMb induced a primary antibody response that was
exclusively of the IgM subclass, and upon rechallenge, elicited a secondary IgG
response (data not shown) . Administration of SpWMb in CFA resulted in a
significant production of IgM, and additionally, the emergence of IgG antibodies
in the primary response. Immunization with KLH in soluble form without
adjuvants elicited a primary IgG response in addition to IgM . We injected
BALB/c mice intraperitoneally with 200 jug anti-L3T4 on 3 consecutive days
(-1, 0, and +1). On day 0, the animals were immunized intraperitoneally with
SpWMb or KLH . As shown in Fig. 3, treatment with antibody prevented a
primary humoral immune response. No specific antibodies against SpWMb orGORONZY ET AL.
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KLH were detected in sera of anti-L3T4-treated mice compared with untreated
controls. However, mice treated with three doses of 10 ug anti-L3T4 had an
almost normal antibody response to both antigens, although this dose of antibody
significantly diminishedthe L3T4+ T cell subpopulation (Table 1) . As determined
in antibody titration experiments, 50 ug anti-L3T4 injected on each of 3
consecutive days was the minimal antibody dose that inhibited humoral immune
responsiveness against SpWMb (data not shown).
Long-term Unresponsiveness of Animals after Treatment In Vivo with Anti-
L3T4. BALB/c mice that had been treated with 3 X 200 ug anti-L3T4 at the
time of primary immunization were subsequently boosted with soluble SpWMb
or KLH at 2 wk intervals. To determine whether immunization with antigen at
the time of the anti-L3T4 treatment was necessary for a specific blockade of the
humoral immune response, two additional treatment groups were studied. Mice
were treated with anti-L3T4 only, and immunizations were started either 2 or 4
wk later. None of the different experimental groups treated with anti-L3T4
developed a detectable IgG response against SpWMb, as shown in Fig. 4A. All
of these groups of mice have been followed for L-120 d. Mice that were
immunized with SpWMbat the time ofantibody injection and those that received
anti-L3T4 treatment 28 d before immunization remained unresponsive, despite
repeated challenge with SpWMb at 14 d intervals.
The antibody-induced elimination of L3T4+ cells, however, could not induce
similar long-term unresponsiveness against KLH (Fig. 4B). BALB/c mice that
had been immunized with KLH 14 d after the anti-L3T4 treatment developed
a primary IgM anti-KLH response, and subsequently, a secondary IgG response.
Animals immunized with KLH 4 wk after anti-L3T4 injection had an almost
normal antibody response to KLH.
Coadministration of KLH together with the anti-L3T4 antibody, however,
decreased the ability of treated animals to develop a normal humoral immune
response. Although originally unresponsive, such animals began to produce anti-
KLH antibodies after the thirdantigenic challenge (4 wk after treatment) . Serum
levels of anti-KLH antibody in mice receiving coincident anti-L3T4 and KLH
were lower than those of L3T4 depleted mice which were immunized with KLH
2 or 4 wk after antibody treatment (Fig. 4B).
Effect of Treatment In Vivo with Anti-L3T4 mAb on Secondary Immune Re-
sponses. Mice were primed with 100 ,ug SpWMb in CFA and rechallenged with
100 mg soluble SpWMb on day 14. Half of the mice were treated with divided
doses of 200,ug anti-L3T4 mAb on the day before, the day of, and the day after
rechallenge. Control mice, primed and rechallenged, increased their antibody
titers against SpWMb from 1 :640 to 1 :10,240 (Fig. 5). Treatment of primed
mice with anti-L3T4 mAb at the time of rechallenge prevented the induction of
a secondary humoral response when measured on day 8 after rechallenge. This
effect of anti-L3T4 mAb treatment on blocking secondary IgG antibody pro-
duction, however, was transient. SpWMb-primed animals, treated with anti-
L3T4, responded to the secondary antigenic challenge after an initial delay (Fig.
6). Just before the third SpWMb injection, the anti-L3T4-treated mice showed
a significant, but diminished IgG antibody response against SpWMb. After the
third immunization, antibody concentrations of treated mice reached the level
that had been seen in the secondary response of control animals. The IgG918
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Long-term inhibition of humoral immunity against SpWMb in mice treated with
anti-L3T4 in vivo. BALB/c mice were treated with anti-L3T4 (200 ug per day for 3 d) and
were immunized with 100 wg soluble SpWMbat the time of treatment (O), and 2 wk (A), and
4 wk after(*) termination of the antibody treatment. One group did not receive antibody
treatment (A). Immunization was started on day0. Each groupof mice was rechallenged with
100,ug antigen every 14 d; serum concentrations of SpWMb IgG were monitored for 56 d.
Results are expressedas means of four mice. (B) Recovery of humoral responsiveness against
KLHin mice treated with anti-L3T4in vivo. Mice were treated with anti-L3T4andimmunized
as described in A, except that 100 jig KLH was used as the immunizing antigen instead of
SpWMb. Results are given as mean serum concentrations of KLH-specific IgG antibodies.
production in the anti-L3T4-treated mice was, however, still diminished when
compared with controls 5 wk after administration of the antibody. Additionally,
anti-L3T4-treated primed animals characteristically showed a delayed respon-
siveness when challenged with antigen (Fig. 6).
Anti-L3T4-treated Mice Have a Normal B Cell Repertoire.
￿
To examine B cell
repertoire in anti-L3T4-treated mice, we measured the LPS-induced production
in vitro ofanti-SpWMb specific antibodies. Spleen cells of treated animals were
polyclonally stimulated with LPS 10 d after injection of a total dose of 600'Ug
anti-L3T4. Supernatants were harvested 3 d later and SpWMb-specific antibodies
were measured in an ELISA system . LPS-stimulated splenic B cells ofanti-L3T4-
treated BALB/c mice produced as much IgM anti-SpWMb as did untreated
controls (Fig. 7).
Effect of Exogenous rIL-2 in L3T4 + T Cell-Depleted Mice.
￿
The Lyt2-,L3T4+ T
cell subset produces the lymphokine IL-2. We asked whether administration in
vivo of exogenous rIL-2 could substitute for the greatly reduced number ofN F
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FIGURE 5. Effect of treatment with monoclonal anti-L3T4 on antibody production to
SpWMb in primed animals. BALB/c mice were immunized with 100 wg SpWMb in CFA. 2
wk later, serum titers of SpWMb-specific IgG (") were obtained and mice were challenged
with 100 jug soluble SpWMb. Half of the mice were treated with a total dose of 600 juganti-
L3T4 given over 3 d ("), the other half remained untreated (O). Antibody responses to the
antigen rechallenge measured on day 8 are shown as means of four mice.
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FIGURE 6. Long-term effect of anti-L3T4 treatment on the humoral responsiveness of
primed animals. BALB/c mice that hadbeen primed to SpWMbwere treated as described in
Fig. 5. Anti-L3T4 treated (") and untreated (O) mice were boosted with 100 jug soluble
SpWMbat 2 wk intervals. Their IgG responses to SpWMb were measured after each antigen
injection. Each groupconsistedof four animals. Results are expressed as means.
919
L3T4+ cells in treated animals and reconstitute immune responsiveness in these
animals. BALB/c mice were depleted of helper cells by injection of anti-L3T4,
immunized with soluble KLH, and treated with three daily doses of 5,000 U
rIL-2 for 3 d. We have previously shown that administration in vivo of this
amount of rIL-2 can induce a polyclonal IgM response that is not dependent on
the presence of antigen (22). The same result was observed in anti-L3T4-treated
animals (Fig. 8, left), suggesting that: (a) L3T4+ T cells might not play a crucial
role in this rIL-2-induced polyclonal IgM response; and that (b) the B cells that920
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FIGURE 7.
￿
B cell response in vitro of spleen cells from anti-L3T4 treated animals. BALB/c
mice were immunized with 100,ug SpWMb; one group (A) was additionally treated with 200
Ag anti-L3T4 on days -1, 0, and 1; a second group (0) did not receive antibody treatment. A
third group did not receive either anti-L3T4 or antigen (/). 10 d after treatment, 106
splenocytes per ml were stimulated with 1% LPS. Culture supernatants were harvested after
3 d, andwere analyzed for IgM antibodies to SpWMb.
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FIGURE 8.
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Humoral responsiveness in mice treated with anti-L3T4 and reconstituted with
rIL-2 in vivo. BALB/c mice were immunized with 100,ug soluble KLH. Mice remained either
untreated (N) or were treated with anti-L3T4 in divided doses of 200 Kg over 3 consecutive
days (0, A). The antibody treated groups received either rIL-2 (0) the 3 d after antigen
injection, or the buffer control (A). rIL-2 was given in three daily doses of 5,000 U. Each
groupconsisted of four mice. Mice were boosted with 100 t+gKLH every 2 wk andsera were
monitored for production of anti-KLH antibodies. The left panel shows IgM titers to KLH 8
dafterprimaryimmunization. IgG titers to KLHwere measured 8dafter the second (middle)
and 8 d after the third antigenic challenge (right). Results are given as means. (p) Normal
mouse serum.
responded to rIL-2 had a normal repertoire, including IgM anti-SpWMb anti-
bodies.
Although the anti-L3T4-treated, KLH-immunized mice developed IgM anti-
bodies to KLH after HL-2 administration, they did not produce a KLH-specific
IgG response after a second antigenic challenge 2 wk later. Thus, administration
of HL-2 was not sufficient to induce memory in anti-L3T4-depleted, antigen-
challenged animals, nor could it induce a class switch from IgM to IgG. The
KLH-immunized mice treated with anti-L3T4 and HL-2 were indistinguishable
from the anti-L3T4-treated mice in the secondary response (Fig. 8, middle;
however, they reacted differently after the third KLH challenge. As shown in
Fig. 8, right, the humoral immune response (IgG anti-KLH) of rIL-2-treated
mice was markedly enhanced compared with the response of animals that hadGORONZY ET AL.
￿
921
not received rIL-2, but administration of rIL-2 did not influence the delay (of
about 4 wk) in the ability ofanti-L3T4-treated mice to mount a humoral immune
response against KLH. It is highly unlikely that the injected rIL-2 persisted in
these animals for a period of4 wk, suggesting that the effect ofrIL-2 on the IgG
production measured in the tertiary and quaternary humoral immune response
had in some way been initiated at the time of the antibody treatment and the
initial immunization.
Discussion
Experiments described in this paper were designed to investigatethe functional
importance of the L3T4+ T cell subset in the initiation and differentiation in
vivo of a humoral immune response against soluble antigens. Effective elimina-
tion of the L3T4+ T cell population prevented the induction of a humoral
immune response against SpWMb, as well as KLH. Abrogation of immune
responses against BSA, OVA, sheep red blood cells, and KLH after the injection
ofanti-L3T4 have been reported (5, 23, 24). In the early posttreatment period,
simple depletion of Th cells could account for the observed immunosuppression
(Fig. 1 and Table I). Interestingly, we did not find a direct correlation between
the reappearance of the L3T4+ T cells and the restoration of the humoral
immune responsiveness. Anti-L3T4 treated mice failed to respond to SpWMb,
whereas a humoral immune response to KLH could be detected as early as 4 wk
after anti-L3T4 treatment.
In addition to the striking reduction in numbers of L3T4+ T cells, an
impairment in APC functionoftreatedanimals early after the antibody treatment
mighthave contributed tothe inhibition ofantibody production. L3T4 molecules
have been shown to be expressed by rat macrophages (25), suggesting that
administration in vivo ofanti-L3T4 might block antibody formation through an
effect on APC function. We saw a transient decrease in APC function after anti-
L3T4 treatment, suggesting the L3T4 moleculesare expressed on murine splenic
APCs (unpublished observations). However, a single effective treatment in vivo
with anti-L3T4 created a persistent inhibition ofthe humoral immune response
for >4 wk, whereas splenic APC function of anti-L3T4-injected animals had
returned to normal levels by 4 wk after antibody treatment. Additional experi-
ments in vitroand in vivo showed that the B cell repertoire oftreated mice was
not affected (Figs. 7 and 8).
Both during titration studies on depletion and after the regeneration of the
L3T4+ T cell subset, a clear difference was observed between the response to
KLH and SpWMb. A 40% reconstitution of the L3T4-expressing T cell popu-
lation was sufficient to induce an antibody response against KLH, but could not
initiate an antibody response against SpWMb. <_90% depletion of L3T4 T cells
affected SpWMb, but not anti-KLH responses. One possible explanation for this
discrepancy, assuming that the elimination, as well as the regeneration of the T
cell repertoire is random, would be that there are significantly less precursors of
SpWMb-reactive T cells compared with KLH-reactive T cells. We have deter-
mined precursor frequencies ofT cells that proliferate in response to SpWMb.
Lymph node cells of a naive DBA/2 mouse contain about 1 in 45,000 anti-
SpWMb proliferative precursors. Priming with soluble antigen increased this
frequency to ^-1 in 12,000 (22). Frequencies of 1 in 6,000 KLH-specific helper922
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cells were reported after immunization of mice with KLH in CFA (26). Thus,
the preexisting T cell repertoire might determine the effects of anti-L3T4 on
specific immune responses. Further evidence that clonal depletion may be one
mechanism ofimmunosuppression after anti-L3T4 treatment in vivo comes from
experiments done in primed animals. L3T4 T cell depletion only transiently
affected antibody production in such mice (Fig. 6). In contrast to primary
responses, as few as 20% recovered helper cells (L3T4+) were sufficient in
primed animals to allow IgG production against SpWMb. The preservation of
memory antibody responses raises the interesting possibility that memory Tcells
may be selectively protected from the effect of in vivo of anti-L3T4.
It is possible that the elimination of L3T4+ helper cells in the adult mouse
could mimic the neonatal state and provide a short "window," allowing specific
tolerance induction to an antigen present during the early phase ofhelper T cell
regeneration . To test for active suppression, we adoptively transferred lymph
node cells from such treated animals into irradiated recipients. In preliminary
experiments, we failed to show antigen-specific suppressor cells (data notshown).
To evaluate the potential importance ofcoincident administration ofantigen on
presumed tolerance induction, we compared humoral responses in animals that
received SpWMb together with the anti-L3T4 injection, with those immunized
with SpWMb 2 or 4 wk after the anti-L3T4 treatment (Fig. 4A). The finding
that the mice that were first challenged with SpWMb 4 wk after antibody
treatment did not develop a humoral immune response against SpWMb might
argue against an antigen-induced unresponsiveness. However, additional exper-
iments are necessary to analyze mechanisms underlying the long-term unrespon-
siveness after treatment in vivo with anti-L3T4.
An altered composition of the L3T4+ population during the regeneration
phase afterantibody-mediatedhelper cell depletionmight significantlycontribute
to the immunosuppressive effect. Evidence for a nonrandom elimination of
L3T4+ T cells and/or a nonrandom recovery of these T cells comes from several
experimental observations. High doses of anti-L3T4 mAb, and thus elimination
of 95% of L3T4+ T cells, were necessary to inhibit anti KLH antibody produc-
tion. However, ?40% recovery ofthe L3T4+ Tcells was required to restore the
response to KLH. Mice primed to SpWMb before anti-L3T4 treatment retained
memory and could induce an anti-SpWMb IgG antibody response (Fig. 6).
Further evidence for functional heterogeneity of the recovering L3T4 popula-
tion was suggested by experiments in which Th cell-depleted mice were recon-
stituted with rIL-2. Mice treated with anti-L3T4 and rIL-2 generated signifi-
cantly higher titers of specific antibodies after the third challenge (Fig. 8). The
possibility that rIL-2-induced a more rapid recovery of T cells in the rIL-2-
treated mice was excluded by two-color FACS analysis (data not shown). The
finding of a delayed but markedly improved humoral immune response in rIL-
2-injected mice suggested that rIL-2 might have expanded an amplifier T cell
subset which potentiated the helper cell function for antibody production once
helper cells reappeared . Our data provide evidence that humoral immunocom-
petence during and after T cell depletion by anti-L3T4 treatment is regulated
by the representation of antigen-specific precursor cells within the T cell pool,
aswellas by additional immunoregulatory events thatmodulate humoral immune
responsiveness. Further experiments are necessary to determine the exact natureGORONZY ET AL.
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of different T cells involved in the reconstitution of a functional T cell compart-
ment.
Summary
mAbs directed against the L3T4 molecule administered in vivo caused a severe
and long lasting helper cell depletion in mice . Regeneration of the L3T4'
subpopulation occurred gradually (2-3 mo) after a single antibody treatment.
Experiments were designed to examine the humoral immunocompetence of such
anti-L3T4-treated animals during and after regeneration of the L3T4' T cell
subset. The animals were injected with anti-L3T4, immunized with soluble
antigen, and challenged with antigen every 2 wk. Antibody responses to two
antigens, sperm whale myoglobin (SpWMb) and KLH, which differ with regard
to their immunogenicity, were compared. The lack of humoral immune respon-
siveness to either of these two antigens shortly after anti-L3T4 treatment was
probably due to clonal depletion . The anti-L3T4-induced immunosuppressive
effect on antibody production seemed to be determined in part by the preexisting
T cell repertoire, as was suggested by the recovery of responsiveness to the
highly immunogenic antigen KLH and the transient inhibitory effect of anti-
L3T4 treatment in primed animals. The regenerating L3T4' T cell subpopula-
tion was relatively incompetent in initiating B cell responses. More than 40% of
the L3T4+ T cell compartment had to recover to provide help for the production
of anti-KLH antibodies, whereas elimination of 90% of the L3T4+ helper cells
did not inhibit a primary anti-KLH response. Evidence for a heterogeneous
composition of the L3T4+ subset came from experiments using rIL-2 in vivo.
The addition of rIL-2 during early helper cell depletion improved the recovery
of the humoral responsiveness without apparently affecting the kinetics of the
regeneration of L3T4' T cells. Interestingly, humoral unresponsiveness to the
weakly immunogenic antigen SpWMb persisted for at least 120 d. This long
lasting unresponsiveness could not be explained by clonal depletion, and sug-
gested as one possibility that the presence of antigen during regeneration of the
L3T4' helper cell population may have influenced the ultimate T cell repertoire.
The authors would like to thank Dr. F. Fitch of the University of Chicago for providing
hybridoma GK 1 .5 . The expert secretarial assistance of Robyn Kizer and Diane O'Neill
in preparing this manuscript is appreciated.
Receivedfor publication 24 February 1986 and in revisedform 21 May 1986.
References
1 . Cosimi, A. B., R. B. Colvin, R. C. Burton, R. H. Rubin, G. Goldstein, P. C. Kung,
W. P. Hansen, F. L. Delmonico, and P. S. Russell. 1981 . Use ofmonoclonal antibodies
to T cell subsets for immunologic monitoring and treatment in recipients of renal
allografts. N. Engl. J. Med. 305:308.
2. Wofsy, D., J. A. Ledbetter, P. L. Hendler, and W. Z. Seaman . 1985. Treatment of
murine lupus with monoclonal anti-T cell antibody.J. Immunol. 134:852.
3 . Waldor, M. K., S. Sriram, R. Hardy, L. A. Herzenberg, L. Lanier, M. Lim, and L.
Steinman. 1985. Reversal ofexperimental allergic encephalomyelitis with monoclonal
antibody to a T-cell subset marker. Science (Wash. DC). 22:415.924
￿
ANTI-L3T4-INDUCED HUMORAL UNRESPONSIVENESS
4. Wofsy, D., and W. E. Seaman. 1985. Successful treatment of autoimmunity in NZB/
NZW F, mice with monoclonal antibody to L3T4J Exp. Med. 161 :378.
5. Cobbold, S. P., A. Jayasuriya, A. Nash, T. D. Prospero, and H. Waldmann. 1984.
Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature
(Lond. ). 312 :548.
6. Fabre, J. W., C. A. Sunderland, and A. F. Williams. 1981 . Immunosuppressive
properties of mouse monoclonal antibodies and rabbit antisera to a leukocyte specific
antigen in the rat. Transplant. Proc. 1 :509.
7. Ritz, J ., and S. F. Schlossman. 1982 . Utilization of monoclonal antibodies in the
treatment of leukemia and lymphoma. Blood. 1 :1 .
8. Dialynas, D. P., Z. S. Quan, K. A. Wall, A. Pierres, J. Quintans, M . R. Loken, M .
Pierres, and F. W. Fitch. 1983. Characterization ofthe murine T cell surface molecule
designated L3T4 identified by monoclonal antibody GK1 .5: similarity of L3T4 to
the human Leu-3/T4 molecule. J. Immunol. 131 :2445.
9. Dialynas, D. P., D. B. Wilde, P . Marrach, A. Pierres, K. A. Wall, W. Harran, G.
Otten, M. R. Loken, M. Pierres, J. Kappler, and F. W. Fitch. 1983 . Characterization
of the murine antigenic determinant designated L3T4a recognized by monoclonal
antibody GK1 .5: expression of L3T4a by functional T cell clones appears to correlate
primarily with class 11 MHC antigen reactivity. Immunol. Rev. 141 :1376.
10. Wilde, D. B., P. Marrack, J . Kappler, D. Dialynas, and F. W. Fitch. 1983 . Evidence
implicating L3T4 in class 11 MHC antigen reactivity: monoclonal antibody GK1 .5
(anti-L3T4a) blocks class II MHC antigen-specific proliferation release lymphokines
and binding by cloned murine helper T lymphocyte lines. J. Immunol. 131 :2178.
11 . Golding, H., J. McCluskey, T. 1 . Munitz, R. N. Germain, D. H . Margulies, and A.
Singer. 1985 . T-cell recognition of a chimaeric class II/class I MHC molecule and
the role of L3T4 . Nature (Lond.). 317:425 .
12. Nossal, G. J. V. 1983 . Cellular mechanisms of immunological tolerance. Annu. Rev.
Immunol. 1 :33 .
13. Klinman, N . R., and J . L. Press. 1975. The characterization of the B-cell repertoire
specific for 2,4-dinitrophenyl and 2,4,6-trinitrophenyl determinants in neonatal
BALB/c mice. J. Exp. Med. 141 :1133.
14. Sigal, N . H., P. J. Press, and N. R. Klinman. 1976. Late acquisition of a germline
specificity. Nature (Lond.). 259:51 .
15. Edinger, H. M., and C. H. Heusser. 1982. Expression of a distinct B-cell clonotype
profile after antigen-induced unresponsiveness. Eur. J. Immunol. 12:533.
16. Thompson, M. A., S. Raychaudhuri, and M. P . Cancro. 1983. Restricted adult clonal
profiles induced by neonatal immunization. Influence of suppressor T cells. J. Exp.
Med. 158 :112.
17. Ledbetter, J. A., R. V. Rouse, H . S. Micklem, and L. A. Herzenberg. 1980 . T cells
subsets defined by expression of Lyt-1,2,3 and Thy-1 antigens. Two parameter
immunofluorescence and cytotoxicity analysis with monoclonal antibodies modifies
current view . J. Exp. Med. 152:280.
18. Goding, J. 1976. Conjugation of antibodies with fluorochromes. Modification of
standard methods. J. Immunol. Methods. 13 :215.
19. Bayer, F. A., and M . Wilcheck. 1978. The avidin-biotin complex as a tool in molecular
biology. Trends Biochem. Sci. 11 :257.
20. Hayaka, K., R. R. Hardy, D. R. Parks, and L. A. Herzenberg. 1983 . The "Ly-1 B"
cell subpopulation in normal, immunodefective, and autoimmune mice. J. Exp. Med.
157:202.
21 . Shigeta, M., S. Takahara, S . J. Knox, T. Ishihara, E. S. Vitetta, and C. G. Fathman.
1986. Two independent pathways of helper activity provided by a single T cell clone.
J. Immunol. 136:34 .GORONZY ET AL .
￿
925
22 . Weyand,C .M .,J . Goronzy, M . J. Dallman, and C . G. Fathman . 1986 . Administration
of recombinant interleukin 2 in vivo induces a polyclonal IgM response . J. Exp. Med.
163 :1607 .
23 . Wofsy, D ., D . C . Mayes, J . Woodcock, and W . E . Seaman . 1985 . Inhibition of
humoral immunity in vivo by monoclonal antibody to L3T4 : studies with soluble
antigens in intact mice .J. Immunol. 135:1698 .
24 . Coulie, P. G ., J . P . Coutelier, C . Uyttenhove, P. Lambotte, and J . Van Snick . 1985 .
In vivo suppression of T-dependent antibody responses by treatment with a mono-
clonal anti-L3T4 antibody. Eur. J . Immunol . 15:638 .
25 . Jefferies, W . A., J . R . Green, and A . F . Williams . 1985 . Authentic T helper CD4
(W3j25) antigen on rat peritoneal macrophages .J. Exp. Med. 162:117 .
26 . Sproviero, J . F .,M .J . Imperiale, andM . Zauderer . 1981 . Clonal analysis of F l hybrid
helper T cells . I-A subregion-encoded hybrid determinants restrict the activity of
keyhole limpet hemocyanin-specific helper T cells .J. Exp. Med . 154:1255 .